Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at $14,219,670.74. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $46.25 on Friday. The firm has a market capitalization of $2.40 billion, a P/E ratio of -37.91 and a beta of 3.57. The stock has a 50-day simple moving average of $43.92 and a two-hundred day simple moving average of $44.52. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The company had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on JANX shares. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Monday, September 16th. Scotiabank dropped their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $66.13.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in JANX. Summit Securities Group LLC purchased a new position in Janux Therapeutics in the second quarter valued at $29,000. Amalgamated Bank grew its position in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Janux Therapeutics in the 2nd quarter valued at about $42,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics in the 2nd quarter worth about $151,000. Finally, AQR Capital Management LLC acquired a new position in Janux Therapeutics in the 2nd quarter worth about $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.